746 results on '"Michels S"'
Search Results
2. Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial
3. Exploring Interprofessional Dynamics: Insights from Reflective Diaries in the Final Clerkship Year
4. Klinische Ergebnisse nach binokularer Implantation einer nicht-diffraktiven, monofokalen, intraokularen Linse mit erweiterter Schärfentiefe in Kombination mit einer Mini-Monovision
5. Collaborative Online International Learning (COIL): Chancen und Herausforderungen für die Lehre in den Gesundheitsberufen
6. Partizipation in den Gesundheitsberufen: Wie gelingt eine erfolgreiche Co-Creation mit studentischen Mitarbeitenden in der medizinischen Ausbildung?
7. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
8. Präzisionspulskapsulotomie: Die neue Kapsulorhexis?
9. Faricimab bei neovaskulärer altersbedingter Makuladegeneration: 48-Wochen-Daten der Studien TENAYA und LUCERNE nach Dosierungskohorten
10. 9P Small-scale ROS1 aberrations: Functional impact and therapeutic potential
11. 1171P A phase II theranostic study with osimertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC) progressing on EGFR tyrosine kinase inhibitors (TKI) and undetectable EGFR T790M (THEROS)
12. EP08.02-114 Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients
13. EP08.02-106 KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations
14. 991P EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)
15. 1028P BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort
16. 1729P The biological effect of small-scale ROS1 aberrations: An in silico analysis
17. 1308P Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations
18. Dynamic Editors for Well-Typed Expressions
19. EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)
20. ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics
21. The biological effect of small-scale ROS1 aberrations: An in silico analysis
22. Small-scale ROS1 aberrations: Functional impact and therapeutic potential
23. BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response - results from the NSCLC cohort
24. 52P ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics
25. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma
26. Cross-Sectional Epidemiological Studies on Arsenic Excretion in Urine of Population in Areas with Different Air Pollution
27. Theme 11 - Cognitive and Psychological Assessment and Support.
28. Dynamic Editors for Well-Typed Expressions
29. The intravitreal injection: Variations in regulations, cost and reimbursement in Europe
30. 1374P Survival and therapy analysis of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients
31. 1336P Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy
32. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial
33. Characterization of Novel Diphenylamine Compounds as Ferroptosis Inhibitors
34. FP14.04 Resistance to MET Inhibition in MET Driven NSCLC and Response after Switching from Type I to Type II MET Inhibitors
35. Combination of verteporfin photodynamic therapy and ranibizumab: effects on retinal anatomy, choroidal perfusion and visual function in the protect study
36. Reduced fluence versus standard photodynamic therapy in combination with intravitreal triamcinolone: short-term results of a randomised study
37. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study
38. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study
39. Value of polarisation-sensitive optical coherence tomography in diseases affecting the retinal pigment epithelium
40. Systemisches und intravitreales Bevacizumab (Avastin®) bei neovaskulärer altersbezogener Makuladegeneration
41. Intravitreales Bevacizumab vs. Verteporfin und intravitreales Triamcinolon Acetonid bei Patienten mit neovaskulärer AMD
42. Rolle der makulären Funktionsanalyse für die Bestimmung der Funktionsfähigkeit der Makula bei charakteristischen Makulapathologien
43. EATON: A phase I dose-escalation trial of nazartinib (EGF816) and trametinib in EGFR-mutant non-small cell lung cancer (NSCLC) - preliminary data
44. Small Cell Lung Cancer - Filling the gap between science and patients
45. KRAS mutations in never-smoker NSCLC patients: Defining a new patient subgroup
46. FIND: a phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC
47. Anti-Angiogenese bei neovaskulärer Makuladegeneration: Neue therapeutische Strategien
48. Dreidimensionale Darstellung photodynamischer Effekte und des Spontanverlaufs bei chorioidalen Neovaskularisationen
49. Photodynamische Therapie bei chorioidalen Hämangiomen: Langzeitergebnisse
50. Chorioretinale Anastomosen als ungünstiger Prognosefaktor bei photodynamischer Therapie
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.